CME Presentations




  • Adolfo Enrique Diaz, MD, MSc

    Adolfo Enrique Diaz, MD, MSc

    Adolfo Enrique Diaz, MD, MSc

    Associate Professor of Medicine, Division of Hematology-Oncology

    Adolfo Diaz, MD, MSc, is an Associate Professor of Medicine in the Division of Hematology- Oncology at UT Health San Antonio. Dr. Diaz completed his medical training with honors at the Pontificia Universidad Javeriana (Colombia) and his Internal Medicine residency at New York University. He completed his Fellowship in Hematology-Oncology and received a Master of Science in Clinical Investigation and Translational Science, both from UT Health Science Center San Antonio. His research and clinical interests focus on improving outcomes in patients with lymphomas and on health care disparities. Currently, Dr. Diaz is the Leader of the Adult Lymphoma Program at Mays Cancer Center and serves as Ambassador and Member of the Committee on Promoting Diversity for the American Society of Hematology.
  • Ashley Bryant, PhD, RN, OCN, FAAN

    Ashley Bryant, PhD, RN, OCN, FAAN

    Ashley Bryant, PhD, RN, OCN, FAAN

    Associate Professor, School of Nursing

    Ashley Bryant, PhD, RN, OCN, FAAN is an experienced oncology, gerontological, and palliative care nurse researcher, educator, and advocate. Dr. Bryant is an Associate Professor in School of Nursing at the University of North Carolina at Chapel Hill School of Nursing and Assistant Director of the Cancer Training Research Education Coordination Core at UNC Lineberger Comprehensive Cancer Center. She is the Program Coordinator for the oncology nursing fellowship. She works at Transitions Lifecare where she cares for individuals during their end-of-life journey. The overarching research goal of her program is to develop, implement, and disseminate palliative and functional interventions starting in the hospital and extending into homes for adults with blood cancers and their caregivers.
  • Christopher Flowers, MD, MS

    Christopher Flowers, MD, MS

    Christopher Flowers, MD, MS

    Chair, Department of Lymphoma/Myeloma

    Christopher Flowers, MD, MS, joined The University of Texas MD Anderson Cancer Center in 2019 as Chair of the Department of Lymphoma/Myeloma and was appointed Division Head ad interim of Cancer Medicine in 2020. Through the pandemic, his leadership contributed to the institution’s recovery in patient volume while maintaining accelerated safety measures. Dr. Flowers’ is a clinician who conducts clinical research involving cancer outcomes and informatics and phase 1/2 trials, focusing on the clinical development of novel therapeutics for B-cell lymphomas. His research interests include patient-oriented research in lymphoma and computer microsimulation models and cost-effectiveness analyses aimed at developing strategies to individualize care for cancer patients and improve systems of care.

CME Information

Collaborating with Patients to Achieve Clinical Trial Equity in Non-Hodgkin Lymphoma
Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.


This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.


This activity was released on March 1, 2023 and is valid until March 1, 2024. Requests for credit must be made no later than March 1, 2024.


The educational design of this activity addresses the needs of community-based hematologic oncologists, hematologists, medical oncologists, oncology advanced practice providers (NPs and PAs), oncology nurses, pharmacists, and other clinicians involved in the management of patients with NHL.


With many diverse racial and ethnic populations (including American Indian/Alaska Native, Black, and Asian/Pacific Islander patients) experiencing low 10-year relative survival rates related to non-Hodgkin lymphoma (NHL), it is important that all patients receive quality care to improve survival. This includes consideration of clinical trials, which often provide patients access to breakthrough treatments and emerging therapeutic options. However, one of the greatest disparities in cancer care is access to clinical trials and ensuring diverse participation.

Join an expert panel of hematology/oncology specialists and advanced practitioners to discuss the implications of the lack of diversity and inclusion in NHL clinical trials. Panelists will share strategies to communicate with patients about the clinical-trial process, help them decipher eligibility criteria, and identify trials that could provide them with unique and effective treatments for NHL.

Education is also available for your patients with NHL. Help dispel the myths and misconceptions about clinical research and direct your patients to to access the activity, “Considering a Clinical Trial as Treatment for Your NHL? Key Questions Answered.”


After completing this activity, the participant should be better able to:
  • Amend the misconceptions of clinicians that inhibit the consideration of clinical trials
  • Assess patient perceptions on participation in clinical research
  • Counsel patients using culturally appropriate skills and furnish patients with clinical-trial education
  • Discuss ongoing clinical trials in NHL that represent new and emerging mechanisms of action and outline their eligibility criteria


JointlyAccreditedProvider Logo
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 60 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Conflicts of Interest
Ashley Leak Bryant, PhD, RN, OCN, FAAN
Associate Professor, School of Nursing
Assistant Director, Cancer Research Training and Education Coordination
The University of North Carolina at Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Researcher: Carevive Systems, Inc., Jazz Pharmaceuticals
Enrique Diaz, MD, MSc
Associate Professor of Medicine
Division of Hematology Oncology
Lead, Adult Lymphoma Program
Mays Cancer Center
UT Health San Antonio
Consultant, Advisor, and Speaker: ADCT, AstraZeneca, Genentech, Incyte/Morphosys, Lilly
Christopher R. Flowers, MD, MS, FASCO
Division Head ad interim, Division of Cancer Medicine
Chair, Professor, Department of Lymphoma/Myeloma
UT MD Anderson Cancer Center
Consultant, Advisor, and Speaker: AbbVie, AstraZeneca, Bayer, BeiGene, Bio Ascend, Bristol Myers Squibb, Celgene, Denovo Biopharma, Foresight Diagnostics, Genentech/Roche, Genmab, Gilead, Karyopharm, Pharmacyclics/ Janssen, Seagen, Spectrum

Stock/stock options private company: Foresight Diagnostics, N Power

Researcher: 4D, AbbVie, Acerta, Adaptimmune, Allogene, Amgen, Bayer, Celgene, Cellectis, EMD Serono, Genentech/Roche, Gilead, Guardant, Iovance, Janssen, Kite, Morphosys, Nektar, Novartis, Pfizer, Pharmacyclics, Sanofi, Takeda, TG Therapeutics, Xencor, Ziopharm

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The PlatformQ Health Education, LLC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support: For additional information about the accreditation of this activity, please visit

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at